Skip to main content
SpringerLink
Log in

‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas

Still a Viable Strategy?

  • Current Opinion
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Observation until the development of symptoms, or ‘watch and wait’, has long been a proposed management technique for patients with indolent lymphomas. However, investigators have found that there may be differences in outcomes for various patient groups according to histopathology, clinical features of the disease, biologic factors as yet to be fully recognized, and type of initial therapy offered. Recently, investigators from the UK National Cancer Research Institute reported that progression-free results were significantly improved when asymptomatic patients with indolent follicular lymphomas received initial therapy with single-agent rituximab rather than when they underwent observation alone. These results were further improved when they received maintenance rituximab. Time to chemotherapy was also longer when these patients received initial therapy with rituximab, thereby delaying the need for such treatment. However, overall survival rates for patients who received rituximab as initial therapy were similar to those for patients who underwent initial ‘watch and wait’. Future studies should concentrate on risks of such management, including cost effectiveness of such treatments and development of resistance to subsequent therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Portlock C, Rosenberg S. No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 10–3

    Article  PubMed  CAS  Google Scholar 

  2. Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311: 1471–5

    Article  PubMed  CAS  Google Scholar 

  3. Anderson T, DeVita V, Simon R, et al. Malignant lymphoma. II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–21

    Article  PubMed  CAS  Google Scholar 

  4. Anderson T, Bender R, Fisher R, et al. Combination chemotherapy in non-Hodgkin’s lymphoma: results of long-term follow-up. Cancer Treat Rep 1977; 61: 1057–66

    PubMed  CAS  Google Scholar 

  5. Rosenberg S. Non-Hodgkin’s lymphoma: selection of treatment on the basis of histologic type. N Engl J Med 1979; 30: 924–8

    Article  Google Scholar 

  6. Glatstein E, Donaldson S, Rosenberg S, et al. Combined modality therapy in malignant lymphomas. Cancer Treat Rep 1977; 61: 1199–207

    Google Scholar 

  7. Soubeyran P, Egbahli H, Trojani F, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? Astudy of 43 consecutive patientsina single center. Ann Oncol 1996; 7: 713–8

    Article  PubMed  CAS  Google Scholar 

  8. Advani R, Rosenberg S, Horning S. Stage I and II follicular non-Hodgkin’ lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–9

    Article  PubMed  Google Scholar 

  9. Gospadarowicz M, Bush R, Brown T, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10: 489–97

    Article  Google Scholar 

  10. Pendlebury S, Awadi M, Askley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin’s lymphoma. Radiother Oncol 1985; 36: 167–71

    Article  Google Scholar 

  11. Vaughan Hudson B, Vaughan Hudson G, MacLennan K, et al. Clinical stage I non-Hodgkin’s lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 1088–93

    Article  PubMed  CAS  Google Scholar 

  12. Denham J, Denham E, Dear K, et al. The follicular non-Hodgkin’s lymphomas — I: the possibility of cure. Eur J Cancer 1996; 32A: 470–9

    Article  PubMed  CAS  Google Scholar 

  13. MacManus M, Hoppe R. Is radiotherapy curative for stage I and IIlow-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–90

    CAS  Google Scholar 

  14. Wilder R, Jones D, Tucker S, et al. Long-term results with radiotherapy for stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219–27

    Article  PubMed  CAS  Google Scholar 

  15. Guadagnolo B, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928–34

    Article  PubMed  Google Scholar 

  16. Ardeshna K, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 2003; 362: 516–22

    Article  PubMed  CAS  Google Scholar 

  17. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 1110–7

    PubMed  CAS  Google Scholar 

  18. Coiffier B, Bastion Y, Berger F, et al. Prognostic factors in follicular lymphoma. Semin Oncol 1993; 86: 1460–3

    Google Scholar 

  19. Young R, Longo D, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality. Semin Hematol 1988; 25 Suppl. 2: 11–6

    PubMed  CAS  Google Scholar 

  20. Ardeshna K, Smith P, Qian W, et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminary analysis [abstract no.6]. Blood 2010; 116: 5

    Google Scholar 

  21. Ardeshna K, Qian W, Stephens R, et al. Preliminary results of quality of life (QoL) analyses from the intergroup phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma [abstract no. 019]. Ann Oncol 2011; 22 Suppl. 4: iv88

    Google Scholar 

  22. Hainsworth J, Litchy S, Shaffer D, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non Hodgkin’s lymphoma — a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–95

    Article  PubMed  CAS  Google Scholar 

  23. Martinelli G, Schmitz S, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480–4

    Article  PubMed  CAS  Google Scholar 

  24. Gordon L, Grow W, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–102

    Article  Google Scholar 

  25. Kahl B, Hong F, Williams M, et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma (late-breaking abstract). Proceedings of the American Society of Hematology, Plenary Session; 2011 Dec 6; San Diego (CA)

    Google Scholar 

  26. Taverna C, Bassi S, Hitz F, et al. Rituximab treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized SAKK 35/03 [abstract no. 1802]. Blood 2010; 116: 752

    Google Scholar 

  27. Berinstein N, Grillo-Lopez A, White C, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998; 9: 995–1001

    Article  PubMed  CAS  Google Scholar 

  28. Pettengell E, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract no. 8005]. J Clin Oncol 2010; 28 Suppl. 15s: 574s

    Google Scholar 

  29. Foa R, Di Rocco A, van Hazel G, et al. Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard and rapid infusion: updated results from the phase IIIb MAXIMA study [abstract no. 3945]. Blood 2010; 116: 1608

    Google Scholar 

  30. Hochster H, Weller E, Gascoyne R, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival inadvanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009; 27: 1607–14

    Article  PubMed  CAS  Google Scholar 

  31. van Oers M, Van Glabbeke M, Giurgeo L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853–8

    Article  PubMed  Google Scholar 

  32. Salles G, Seymour J, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011; 377: 42–51

    Article  PubMed  CAS  Google Scholar 

  33. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. New Engl J Med 1993; 329: 1608–14

    Article  PubMed  CAS  Google Scholar 

  34. Steward W, Crowther D, McWilliam L, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’s lymphoma. Cancer 1988; 61: 441–7

    Article  PubMed  CAS  Google Scholar 

  35. Romaguera J, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma. Cancer 1991; 61: 441–7

    Google Scholar 

  36. Soubeyran P, Eghbali H, Bonichon F, et al. Low-grade follicular lymphomas: analysisof prognosis ina series of 281 patients. Eur J Cancer 1991; 27: 1606–13

    Article  PubMed  CAS  Google Scholar 

  37. Bastion Y, Berger F, Bryon P, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 Suppl. 2: 123–34

    Article  PubMed  Google Scholar 

  38. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Am J Med 1991; 114: 855–60

    CAS  Google Scholar 

  39. Leonard R, Hayward R, Prescott R, et al. The identification of discrete prognostic groups in low-grade non-Hodgkin’s lymphoma: The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1992; 2: 655–62

    Google Scholar 

  40. Horning S. Natural history of and therapy for the indolent non-Hodgkin’ lymphomas. Semin Oncol 1993; 20: 75–80

    PubMed  CAS  Google Scholar 

  41. Cameron D, Leonard R, Mao J, et al. Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma 1993; 10: 89–99

    Article  PubMed  CAS  Google Scholar 

  42. Gospodarowicz M, Bush R, Brown T, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1994; 10: 489–92

    Article  Google Scholar 

  43. Denham J, Denham E, Dear K, et al. The follicular non-Hodgkin’s lymphomas, II. Prognostic factors: what do they mean? Eur J Cancer 1996; 32A: 480–90

    Article  PubMed  CAS  Google Scholar 

  44. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III–IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients. A study of the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1999; 17: 2499–505

    PubMed  CAS  Google Scholar 

  45. Federico M, Vitolo U, Zinzani P, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysisof 987 cases. Blood 2000; 95: 783–9

    PubMed  CAS  Google Scholar 

  46. Maartense E, Le Cessie S, Kluin-Nelemans H, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’s lymphoma registry. Ann Oncol 2002; 13: 1275–84

    Article  PubMed  CAS  Google Scholar 

  47. Lopez-Guillermo A, Monserrat E, Bosch F, et al. Applicability of the International Prognostic Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–6

    PubMed  CAS  Google Scholar 

  48. Aviles A. The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol 1994; 12: 2766–70

    PubMed  CAS  Google Scholar 

  49. Bastion U, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular patients? J Clin Oncol 1994; 12: 1340–2

    PubMed  CAS  Google Scholar 

  50. Hermans J, Krol A, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460–3

    PubMed  CAS  Google Scholar 

  51. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III–IV patients. Ann Oncol 1997; 8 Suppl. 1: S49–52

    Article  Google Scholar 

  52. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104: 1258–65

    Article  PubMed  CAS  Google Scholar 

  53. Formica V, Norman A, Cunningham D, et al. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol 2009; 122: 193–9

    Article  PubMed  CAS  Google Scholar 

  54. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–8

    Article  PubMed  CAS  Google Scholar 

  55. Federico M, Bellei M, Marcheselli L, et al. Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor project. J Clin Oncol 2009; 27: 4555–62

    Article  PubMed  Google Scholar 

  56. Terol M, Teruel A, Amat P, et al. The FLIPI2 score predicts progression-free survival (PFS) and overall survival (OS) in an independent series of follicular lymphoma: a single institution experience [abstract no. 3128]. Blood 2010; 116: 1288

    Google Scholar 

  57. Numata A, Fujimaki K, Tomita N, et al. Retrospective study of the utility of Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 in patients with follicular lymphoma uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [abstract no. 3100]. Blood 2010; 116: 1278

    Google Scholar 

  58. Rummel M. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw 2010; 8: S1–S14

    PubMed  Google Scholar 

  59. Perea G, Altes A, Montoto S, et al. Prognostic indices in follicular lymphoma: a comparison of different prognostic scoring systems. Ann Oncol 2005; 16: 1508–13

    Article  PubMed  CAS  Google Scholar 

  60. Gine E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17: 1539–45

    Article  PubMed  CAS  Google Scholar 

  61. Friedberg J, Taylor M, Cerhan J, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol 2009; 27: 1202–8

    Article  PubMed  Google Scholar 

  62. Gallagher C, Gregory W, Jones A, et al. Follicular lymphomas: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–80

    PubMed  CAS  Google Scholar 

  63. Shustik J, Quinn M, Connors J, et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 2011; 22: 1164–9

    Article  PubMed  CAS  Google Scholar 

  64. Hans C, Weisenburger D, Vose J, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363–7

    Article  CAS  Google Scholar 

  65. Ganti A, Weisenburger D, Smith L, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920–7

    Article  PubMed  CAS  Google Scholar 

  66. Bartlett N, Rizeq M, Dorfman R, et al. Follicular large-cell lymphoma: intermediate or low-grade? J Clin Oncol 1994; 12: 1349–57

    PubMed  CAS  Google Scholar 

  67. Rodriguez J, McLaughlin P, Hagemeister F, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2002–7

    Google Scholar 

  68. Wendum D, Sebban C, Gaulard P, et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. J Clin Oncol 1997; 15: 1654–63

    PubMed  CAS  Google Scholar 

  69. Bierman P. Natural history of follicular grade 3 non-Hodgkin’s lymphoma. Curr Opin Oncol 2007; 19: 433–7

    Article  PubMed  Google Scholar 

  70. Chau I, Jones R, Cunningham D, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36–42

    Article  PubMed  CAS  Google Scholar 

  71. Miller T, Grogan T, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460–6

    PubMed  CAS  Google Scholar 

  72. Frost M, Newell J, Lones M, et al. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384–90

    Article  PubMed  Google Scholar 

  73. Thorns C, Kalies K, Fischer U, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 2007; 50: 716–9

    Article  PubMed  CAS  Google Scholar 

  74. Naresh K. MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007; 92: 267–8

    Article  PubMed  Google Scholar 

  75. Llanos M, Alvarez-Arguelles H, Aleman R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001; 18: 15–22

    Article  PubMed  CAS  Google Scholar 

  76. Broyde A, Boycov O, Strenov Y, et al. Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma. Am J Hemotol 2009; 84: 338–43

    Article  Google Scholar 

  77. Salto B, Shiozawa E, Yamochi-Onizuka T, et al. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol Int 2004; 54: 667–74

    Article  Google Scholar 

  78. Wang S, Wang L, Hochberg E, et al. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005; 29: 1490–6

    Article  PubMed  Google Scholar 

  79. Glas A, Kersten M, Delahaye L, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301–7

    Article  PubMed  CAS  Google Scholar 

  80. Michaels J, Foria V, Mead B, et al. Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 2006; 132: 743–6

    Article  Google Scholar 

  81. Zhao W, Daneshpouy M, Mounier N, et al. Prognostic significance of bcl-cL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004; 103: 695–7

    Article  PubMed  CAS  Google Scholar 

  82. Gulmann C, Espina V, Petricoin E, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors infollicular lymphoma. Clin Cancer Res 2005; 11: 5847–55

    Article  PubMed  CAS  Google Scholar 

  83. Torlakovic E, Bilalovic N, Golouh R, et al. Prognostic significance of PU.1 in follicular lymphoma. J Pathol 2006; 209: 352–9

    Article  PubMed  CAS  Google Scholar 

  84. O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008; 112: 3126–9

    Article  PubMed  Google Scholar 

  85. Bjorck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005; 105: 2908–15

    Article  PubMed  Google Scholar 

  86. Krishnadasan R, Bifulco C, Kim J, et al. Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. Brit J Haematol 2006; 135: 72–5

    Article  Google Scholar 

  87. Koster A, van Krieken J, Mackenzie M, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154–61

    PubMed  CAS  Google Scholar 

  88. Farinha P, Masouldi H, Skinnider B, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–74

    Article  PubMed  CAS  Google Scholar 

  89. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440–6

    Article  PubMed  CAS  Google Scholar 

  90. Wahlin B, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16: 637–50

    Article  PubMed  CAS  Google Scholar 

  91. Dave S, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–69

    Article  PubMed  CAS  Google Scholar 

  92. Sakhinia E, Glennie C, Hoyland J, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109: 3922–8

    Article  PubMed  CAS  Google Scholar 

  93. Glas A, Knoops L, Delahaye L, et al. Gene-expression and immuno-histochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosisoffollicular lymphoma. JClin Oncol 2007; 25: 390–8

    Article  CAS  Google Scholar 

  94. Alvaro T, Lejeune M, Camacho F, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91: 1605–12

    PubMed  CAS  Google Scholar 

  95. Taskinen M, Karjalainen-Lindsberg M, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784–9

    Article  PubMed  CAS  Google Scholar 

  96. Alvaro T, Lejeune M, Salvado M, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–7

    Article  PubMed  Google Scholar 

  97. Farinha P, Campo E, Banham A, et al. The architectural pattern of FOXP3+ T cells is an independent predictor of survival in patients with follicular lymphoma (FL) [abstract]. Mod Pathol 2006; 19: 1043a

    Google Scholar 

  98. Farinha P, Han J, Al-Tourah A, et al. The tumor microenvironment measured by flow cytometry predicts overall survival and transformation risk in follicular lymphoma [abstract no. 2406]. Blood 2006; 108

  99. Ai W, Czerwinski D, Horning S, et al. Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma [abstract no. 824]. Blood 2006; 108

  100. Lee A, Clear A, Calaminici M, et al. Number of CD 4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052–9

    Article  PubMed  CAS  Google Scholar 

  101. Carreras J, Lopez-Guillermo A, Fox B, et al. High numbers of tumorinfiltrating FOXP-3 regulatory T cells are associated with improved survival in follicular lymphoma. Blood 2006; 108: 2957–64

    Article  PubMed  CAS  Google Scholar 

  102. Strickler J, Copenhaver C, Rojas V, et al. Comparison of host cell infiltrates: in patients with follicular lymphoma with and without spontaneous regression. Am J Clin Pathol 1988; 90: 257–61

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. MD Anderson Cancer Center, Houston, TEXAS, USA

    Fredrick B. Hagemeister

Authors
  1. Fredrick B. Hagemeister
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fredrick B. Hagemeister.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagemeister, F.B. ‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas. BioDrugs 26, 363–376 (2012). https://doi.org/10.1007/BF03261894

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03261894

Keywords

Search

Navigation